114 Chapter 5 Group Estimate (95% CI) 8 mg/kg 1 Fixed dose tocilizumab -0.35 (-1.46 to 0.75) Low dose tocilizumab -3.05 (-4.29 to -1.80) Sarilumab 400mg -2.71 (-3.81 to -1.62) Supplementary Table 8. Multivariable linear regression analysis, differences in hospital LOS between different treatment groups, corrected for age, sex, immunocompromised status and Charlson Comorbidity index. For patients with 2 COVID-19 hospital admissions with <90 days in between, 25% was randomly selected and their hospital LOS consisted of the first admission only Group Estimate (95% CI) 8 mg/kg 1 Fixed dose tocilizumab -0.75 (-1.85 to 0.35) Low dose tocilizumab -3.07 (-4.31 to -1.84) Sarilumab 400mg -2.65 (-3.73 to -1.56) Supplementary Table 9. Multivariable linear regression analysis, differences in hospital LOS between different treatment groups, corrected for age, sex, immunocompromised status and Charlson Comorbidity index. For patients with 2 COVID-19 hospital admissions with <90 days in between, 50% was randomly selected and their hospital LOS consisted of the first admission only Supplementary Figure 4. The number of hospital admissions in each month (left y-axis, bars) and the median hospital LOS in days (right y-axis, points) during the study period
RkJQdWJsaXNoZXIy MTk4NDMw